TP-122A

TP-122A is a bacteriophage cocktail composed of three lytic bacteriophages specifically targeting *Pseudomonas aeruginosa*. It is being developed as an inhaled therapy for the treatment of ventilator-associated pneumonia (VAP) in adults, particularly those infections caused by *P. aeruginosa*. The drug is administered via nebulization in addition to standard-of-care antibiotic therapy, with the aim of improving outcomes for patients with VAP who are at high risk due to multidrug-resistant bacterial infections. TP-122A represents one component (component A) of a broader phage cocktail (TP-122), which also includes a separate component targeting *Klebsiella pneumoniae*.